Stefan Tekel invited as TA for 2018 CSHL Synthetic Biology summer course

Posted on

Stefan Tekel, a Biodesign graduate student in the Haynes lab, will be joining a team of four professors and teaching assistants this year at Cold Spring Harbor Laboratory. He will serve as teaching assistant for a CSHL Synthetic Biology Summer Course module led by Dr. Karmella Haynes. The module, called “Chromatin – Design, Build, Test” features Stefan’s latest first-authored work as the main topic. CSHL students will learn how to design and construct fusion proteins, produce these in a cell-free expression system, and test the proteins’ activities in a biochemical assay. Several new, unpublished designs will be tested, and successful candidate proteins will be used to control gene expression in a cultured human cell line. The TA position is a very prestigious and unique opportunity to meet leaders in synthetic biology (invited speakers) and to explore new projects while teaching synthetic biology lab techniques to a select group of talented students.

Advertisements

Cassandra Barrett shares Synthetic Biology with high school ambassadors for STEM

Posted on Updated on

Cassandra Barrett, a Biodesign graduate student in the Haynes lab, led a session on synthetic biology design for students from Arizona’s Chief Science Officer (CSO) Program on Wednesday, July 19, 2018. The event was hosted by the Ira A. Fulton Schools of Engineering.

Read the rest of this entry »

Research – JCR – An inhibitor screen identifies histone-modifying enzymes as mediators of polymer-mediated transgene expression from plasmid DNA

Posted on Updated on

An inhibitor screen identifies histone-modifying enzymes as mediators of polymer-mediated transgene expression from plasmid DNA
Christensen MD, Nitiyanandan R, Meraji S, Davis R, Godeshala S, Goklany S, Haynes KA, Rege K. (2018) Journal of Controlled Release. 286:210-223. https://doi.org/10.1016/j.jconrel.2018.06.030

Delivery of synthetic DNA into cells is a cornerstone technology for gene therapy, gene editing, and basic research. However, consistently efficient delivery of DNA into cells without the aid of engineered viruses still remains out of reach. In previous work, the Rege (chemical engineering) and Haynes (epigenetic engineering) labs reported that treating cells with a small molecule compound that disrupts the arrangement of protein-DNA complexes in the nucleus (chromatin) leads to enhanced uptake and expression of synthetic DNA. In our newest report, we describe the results of a screen of 89 different compounds that target different components of chromatin. We observed that that exogenous plasmids interact with endogenous core histone H3, and that inhibition of histone deacetylases (HDACs) increases nuclear entry of plasmid in UMUC3 bladder cancer cells.

Dr. Haynes invited to speak at University of Oregon

Posted on

Dr. Haynes has been invited to the University of Oregon to present a talk entitled “Drugging the cancer epigenome with synthetic chromatin-based proteins” for the Engineering Biomolecules Mini-Symposium on Friday, June 22, 2018 in the Willamette Hall. The mini-symposium is organized by students in the University of Oregon’s Molecular Biology and Biophysics training program, and showcases six world-class researchers from the field of biomolecular engineering.

Dr. Haynes invited to NCI CSSI Science Day Workshop

Posted on

Dr. Haynes has been invited to the 6th Annual NCI CSSI Science Day Workshop, hosted by the NIH Center for Strategic Scientific Initiatives (CSSI), National Cancer Institute (NCI) in Bethesda, MD. The NCI CSSI has hosted Science Day meetings to convene extramural investigators and NIH/NCI program staff with the goal of facilitating scientific conversations and identifying needs and opportunities across cancer research. Dr. Haynes will present a talk entitled “Engineered chromatin to support epigenetic research and drug development for cancer” on Thursday, June 7, 2018 at the Porter Neuroscience Research Center.

Research – ACS Biochemistry – Design, construction, and validation of histone-binding effectors in vitro and in cells

Posted on Updated on

Design, construction, and validation of histone-binding effectors in vitro and in cells
Tekel SJ, Barrett CM, Vargas DA, Haynes KA. (2018) ACS Biochemistry. 57:4707–4716. https://pubs.acs.org/doi/10.1021/acs.biochem.8b00327

In a special topic issue from ACS Biochemistry: From the Bench, we describe our workflow for quick screening and validation of customized histone-binding fusion proteins. Since our previous report where we enhanced the activity of one such fusion called PcTF, we modified our procedure to circumvent the need to generate large quantities of fusion proteins in bacterial cultures. Instead, we use cell-free transcription-translation (TXTL) to generate small batches of variant proteins, quantify the product with ELISA, and determine relative avidities using immobilized histone peptides in an ELISA format. We demonstrate that relative binding determined by ELISA is consistent with the strength of gene-regulation activity at a target gene in HEK293 cells. Our ongoing work aims to miniaturize this technique even further for rapid exploration of the vast design space for synthetic epigenetic effectors.

Dr. Haynes visits Mayo Clinic AZ to discuss synthetic biology and cancer

Posted on Updated on

Synthetic biology is a field that aims to use what basic research has taught us about DNA and proteins to design and build “living nanotech” that controls cell behavior. Dr. Haynes was invited to present her latest work on synthetic proteins to control gene expression in cancer as part of the Mayo Clinic‘s “Science of Medicine” seminar series. She presented a talk entitled “Engineered chromatin systems to support epigenetic therapy of cancer” on Thursday, May 24, 2018 in the Johnson Research Building and visited with several outstanding Mayo Clinic researchers to discuss the intersection of protein engineering with epigenetic medicine to treat mixed myeloid leukemias and other devastating cancers. Haynes hopes to continue such conversations so that her research can be informed by clinical needs, and even become part of new clinical collaborations.